Mazdutide: The First GLP-1/Glucagon Dual Agonist, and What the Trials Actually Show
Mazdutide is a once-weekly GLP-1/glucagon dual agonist with strong phase 3 evidence (up to ~20% weight loss) — but it is China-only and largely untested elsewhere.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-13A real, China-approved GLP-1/glucagon dual agonist with substantial RCT evidence (GLORY-1 ~14%, GLORY-2 ~20%) — but the data are almost entirely from Chinese adults, it is not FDA/EMA-approved, and long-term/cardiovascular outcomes are missing.
GLP-1/glucagon dual agonist (oxyntomodulin-derived); the glucagon arm adds energy expenditure and hepatic fat effects.
Mechanism established; the record is human-trial-led.
Phase 1b/2/3 RCTs incl. pivotal GLORY-1 (NEJM, ~14% at 6 mg); GLORY-2 (~20% at 9 mg) is company-reported and not yet fully peer-reviewed.
Robust weight loss and liver-fat reduction, but below high-dose tirzepatide/retatrutide on raw weight loss; data almost entirely in Chinese adults.
Reasonable trial data (GI-dominant); long-term/CV/renal outcome data missing; glucagon-arm heart-rate/glucose considerations.
Approved in China (NMPA, 2025) for weight management and type 2 diabetes; not FDA/EMA-approved.
Solid within the studied (largely Chinese) population; generalisability and long-term outcomes open.
Approved only in China; outside that supply chain it is unregulated grey-market, and the glucagon arm adds CV/glycaemic considerations.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A GLP-1/glucagon dual agonist with substantial randomised evidence — but almost entirely in Chinese adults, where it is approved; it is not FDA/EMA-approved, and long-term/cardiovascular-outcome data are missing.
Safety snapshot
Trial safety is GI-dominant; the glucagon arm adds heart-rate and glucose considerations, long-term and pregnancy data are absent, and outside its approval the supply is unregulated.
Regulatory & legality
Approved only in China (prescription-only there); elsewhere it is unapproved and grey-market.
Where claims can exceed the evidence
The evidence is real but region-specific and below high-dose tirzepatide/retatrutide on weight loss; it does not transfer to unsupervised or off-label use.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Mazdutide (also known as IBI362 and LY3305677) is one of the rare compounds discussed in self-experimenter circles that actually has a deep clinical record behind it. It is a once-weekly injectable that activates two receptors at once — the GLP-1 receptor and the glucagon receptor — making it the first approved drug of its class anywhere in the world.
The evidence is genuinely strong by peptide standards. There are published phase 1b, phase 2 and phase 3 trials, including the pivotal GLORY-1 study in the New England Journal of Medicine, which reported 14.0% weight loss at the 6 mg dose over 48 weeks [1]. A higher-dose follow-up, GLORY-2, reported up to roughly 20% weight loss at 9 mg [11]. China's regulator approved it for chronic weight management in June 2025 and for type 2 diabetes in September 2025 [12].
The single biggest caveat is geography. Almost every efficacy figure comes from Chinese adults in trials sponsored by Innovent Biologics, and it is not approved by the FDA or EMA. So while the data are real, how well they generalise — and what long-term and cardiovascular outcomes look like — remains open.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
Adipotide: The Fat-Vessel Killer That Stalled in Humans
Adipotide melts white fat by destroying the blood vessels feeding it. Striking animal data, zero human efficacy evidence, and kidney toxicity that ended its development.
AOD-9604: The Fat-Loss Peptide That Failed Its Own Trial
AOD-9604 is a growth-hormone fragment with strong fat-loss data in animals — but its pivotal human obesity trial failed, and it was never approved as a medicine.
Cagrilintide: The Amylin Analogue Behind CagriSema
A plain-English, evidence-first look at cagrilintide — the long-acting amylin analogue, its trial record, doses studied, and why it is almost never used alone.
Retatrutide: The Triple Agonist Pushing Weight Loss Past Everything Before It
An evidence-first look at retatrutide, the investigational GLP-1/GIP/glucagon triple agonist posting the largest weight-loss numbers seen in any incretin trial to date.